Biotech Archives - Page 662 of 733

1 minute read

Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer

September 12, 9:15 AM

Clinical-stage biotech Cardiff Oncology Inc (NASDAQ:CRDF) announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC)…

CRDF

1 minute read

BeiGene’s Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors

By Vandana Singh

September 12, 9:08 AM

BeiGene Limited (NASDAQ:BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO)…

BAYRY

1 minute read

Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate

By Ragothaman Srinivasan

September 12, 8:49 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).

MRSN

1 minute read

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy To Be Presented At The Rivkin Center & American Association Of Cancer Research 14th Biennial Ovarian Cancer Research Symposium

By Benzinga Newsdesk

September 12, 8:32 AM

Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose

ANIX

2 minute read

Mersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer

By Benzinga Newsdesk

September 12, 8:20 AM

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical

MRSN

1 minute read

Gamida Cell Presents Data Demonstrating The Impact Of Transplantation With Omidubicel For Patients With Hematologic Malignancies At 2022 Cord Blood Connect Meeting

By Benzinga Newsdesk

September 12, 8:16 AM

- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB) - If approved, Omidubicel is

GMDA

3 minute read

NuCana Presents Data On NUC-3373 At The European Society Of Medical Oncology Annual Meeting 2022

By Benzinga Newsdesk

September 12, 8:10 AM

NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients Randomized Study of NUFIRI vs.

NCNA

3 minute read

Onconova Therapeutics Announces Updated Data From Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib In Combination With Nivolumab In Advanced KRAS-Mutated Non-Small Cell Lung Cancer At The ESMO Congress 2022

By Bill Haddad

September 12, 8:04 AM

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3

ONTX

1 minute read

Phio Pharmaceuticals Announces Acceptance Of Six Abstracts At The 37th Annual Meeting Of The Society For Immunotherapy Of Cancer

By Bill Haddad

September 12, 7:34 AM

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

PHIO

1 minute read

Alector Initiates Phase 1 Clinical Trial Of AL044 For The Treatment Of Alzheimer’s Disease

By Benzinga Newsdesk

September 12, 7:12 AM

AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies through

ALEC